Literature DB >> 16926358

Medicare's requirement for research participation as a condition of coverage: is it ethical?

Steven D Pearson1, Franklin G Miller, Ezekiel J Emanuel.   

Abstract

Mesh:

Year:  2006        PMID: 16926358     DOI: 10.1001/jama.296.8.988

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  13 in total

Review 1.  Using comparative effectiveness research to inform policy and practice in the UK HHS: past, present and future.

Authors:  Kalipso Chalkidou; Tom Walley
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Medicare's policy on carotid stents limited use to hospitals meeting quality guidelines yet did not hurt disadvantaged.

Authors:  Peter W Groeneveld; Andrew J Epstein; Feifei Yang; Lin Yang; Daniel Polsky
Journal:  Health Aff (Millwood)       Date:  2011-02       Impact factor: 6.301

3.  Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research.

Authors:  Kalipso Chalkidou; Andrew Hoy; Peter Littlejohns
Journal:  J R Soc Med       Date:  2007-10       Impact factor: 5.344

Review 4.  From evidence to clinical practice in blood and marrow transplantation.

Authors:  Nandita Khera
Journal:  Blood Rev       Date:  2015-04-19       Impact factor: 8.250

5.  Access with evidence development: the US experience.

Authors:  Penny E Mohr; Sean R Tunis
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

6.  Access with evidence development in the UK: past experience, current initiatives and future potential.

Authors:  Andrew Briggs; Karen Ritchie; Elisabeth Fenwick; Kalipso Chalkidou; Peter Littlejohns
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 7.  Cost, coverage, and comparative effectiveness research: the critical issues for oncology.

Authors:  Steven D Pearson
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

8.  Reference pricing with evidence development: a way forward for proton therapy.

Authors:  Justin E Bekelman; Stephen M Hahn
Journal:  J Clin Oncol       Date:  2014-04-21       Impact factor: 44.544

9.  Gatekeepers for pragmatic clinical trials.

Authors:  Danielle M Whicher; Jennifer E Miller; Kelly M Dunham; Steven Joffe
Journal:  Clin Trials       Date:  2015-09-15       Impact factor: 2.486

10.  Paying for prevention: challenges to health insurance coverage for biomedical HIV prevention in the United States.

Authors:  Kristen Underhill
Journal:  Am J Law Med       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.